These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 39208743)

  • 1. Discovery of novel BCL6-Targeting PROTACs with effective antitumor activities against DLBCL in vitro and in vivo.
    Mi D; Li C; Li Y; Yao M; Li Y; Hong K; Xie C; Chen Y
    Eur J Med Chem; 2024 Nov; 277():116789. PubMed ID: 39208743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of
    Guo W; Xing Y; Zhang Q; Xie J; Huang D; Gu H; He P; Zhou M; Xu S; Pang X; Liu M; Yi Z; Chen Y
    J Med Chem; 2020 Jan; 63(2):676-695. PubMed ID: 31895575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
    Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
    Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
    Cardenas MG; Yu W; Beguelin W; Teater MR; Geng H; Goldstein RL; Oswald E; Hatzi K; Yang SN; Cohen J; Shaknovich R; Vanommeslaeghe K; Cheng H; Liang D; Cho HJ; Abbott J; Tam W; Du W; Leonard JP; Elemento O; Cerchietti L; Cierpicki T; Xue F; MacKerell AD; Melnick AM
    J Clin Invest; 2016 Sep; 126(9):3351-62. PubMed ID: 27482887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo.
    Xing Y; Guo W; Wu M; Xie J; Huang D; Hu P; Zhou M; Zhang L; Zhang Q; Wang P; Wang X; Wang G; Wu H; Zhou C; Chen Y; Liu M; Yi Z; Sun Z
    Cancer Lett; 2022 Mar; 529():100-111. PubMed ID: 34990752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.
    Zhang X; Duan YT; Wang Y; Zhao XD; Sun YM; Lin DZ; Chen Y; Wang YX; Zhou ZW; Liu YX; Jiang LH; Geng MY; Ding J; Meng LH
    Acta Pharmacol Sin; 2022 Jan; 43(1):209-219. PubMed ID: 33782541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.
    Li J; Huang Y; Zhang Y; Wen J; Chen Y; Wang L; Jiang P; Hu J
    Med Oncol; 2021 Feb; 38(4):33. PubMed ID: 33629212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6.
    McCoull W; Cheung T; Anderson E; Barton P; Burgess J; Byth K; Cao Q; Castaldi MP; Chen H; Chiarparin E; Carbajo RJ; Code E; Cowan S; Davey PR; Ferguson AD; Fillery S; Fuller NO; Gao N; Hargreaves D; Howard MR; Hu J; Kawatkar A; Kemmitt PD; Leo E; Molina DM; O'Connell N; Petteruti P; Rasmusson T; Raubo P; Rawlins PB; Ricchiuto P; Robb GR; Schenone M; Waring MJ; Zinda M; Fawell S; Wilson DM
    ACS Chem Biol; 2018 Nov; 13(11):3131-3141. PubMed ID: 30335946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCL6 confers resistance to HDAC inhibitors in DLBCL.
    Fan G; Zhang Y; Li Q; Rong R; Chen S; He L; Li B; Zhuang W
    Biochem Pharmacol; 2024 Sep; 227():116466. PubMed ID: 39102989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
    He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.
    Cerchietti LC; Hatzi K; Caldas-Lopes E; Yang SN; Figueroa ME; Morin RD; Hirst M; Mendez L; Shaknovich R; Cole PA; Bhalla K; Gascoyne RD; Marra M; Chiosis G; Melnick A
    J Clin Invest; 2010 Dec; 120(12):4569-82. PubMed ID: 21041953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL.
    Fu L; Zhang J; Shen B; Kong L; Liu Y; Tu W; Wang W; Cai X; Wang X; Cheng N; Xia M; Zhou T; Liu Q; Xu Y; Yang J; Gavine P; Philippar U; Attar R; Edwards JP; Venable JD; Dai X
    J Med Chem; 2021 Aug; 64(15):10878-10889. PubMed ID: 34279092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieving
    Bellenie BR; Cheung KJ; Varela A; Pierrat OA; Collie GW; Box GM; Bright MD; Gowan S; Hayes A; Rodrigues MJ; Shetty KN; Carter M; Davis OA; Henley AT; Innocenti P; Johnson LD; Liu M; de Klerk S; Le Bihan YV; Lloyd MG; McAndrew PC; Shehu E; Talbot R; Woodward HL; Burke R; Kirkin V; van Montfort RLM; Raynaud FI; Rossanese OW; Hoelder S
    J Med Chem; 2020 Apr; 63(8):4047-4068. PubMed ID: 32275432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein-Protein Interaction Interface.
    Sameshima T; Yamamoto T; Sano O; Sogabe S; Igaki S; Sakamoto K; Ida K; Gotou M; Imaeda Y; Sakamoto J; Miyahisa I
    Biochemistry; 2018 Feb; 57(8):1369-1379. PubMed ID: 29293322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.
    Li J; Qian C; Zhou Q; Li J; Li K; Yi P
    Biochem Biophys Res Commun; 2017 Sep; 491(4):939-945. PubMed ID: 28756223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.
    McCoull W; Abrams RD; Anderson E; Blades K; Barton P; Box M; Burgess J; Byth K; Cao Q; Chuaqui C; Carbajo RJ; Cheung T; Code E; Ferguson AD; Fillery S; Fuller NO; Gangl E; Gao N; Grist M; Hargreaves D; Howard MR; Hu J; Kemmitt PD; Nelson JE; O'Connell N; Prince DB; Raubo P; Rawlins PB; Robb GR; Shi J; Waring MJ; Whittaker D; Wylot M; Zhu X
    J Med Chem; 2017 May; 60(10):4386-4402. PubMed ID: 28485934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
    Guo X; Yang D; Fan Z; Zhang N; Zhao B; Huang C; Wang F; Ma R; Meng M; Deng Y
    Eur J Med Chem; 2019 Sep; 178():767-781. PubMed ID: 31234030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAK1 is a druggable kinase for diffuse large B-cell lymphoma.
    Wu Y; Yang R; Ming Y; Xu Y; Chen H; Yao M; Chen X; Mao R; Fan Y
    Cell Biochem Funct; 2019 Apr; 37(3):153-160. PubMed ID: 30907011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wilms' tumor 1-associating protein plays an aggressive role in diffuse large B-cell lymphoma and forms a complex with BCL6 via Hsp90.
    Kuai Y; Gong X; Ding L; Li F; Lei L; Gong Y; Liu Q; Tan H; Zhang X; Liu D; Ren G; Pan H; Shi Y; Berberich-Siebelt F; Mao Z; Zhou R
    Cell Commun Signal; 2018 Aug; 16(1):50. PubMed ID: 30143009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins.
    Du Y; Shi S; Shu C; He Y; Xu W; Wu D; Tian Y; Kong M; He J; Xie W; Qiu Y; Xu Y; Zou Y; Zhu Q
    Eur J Med Chem; 2024 Jun; 272():116489. PubMed ID: 38759458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.